Stakeholders' Contributions - CND 2024 Midterm Review

In CND resolution 66/1, entitled “Preparations for the midterm review to be held during the sixty-seventh session of the Commission on Narcotic Drugs, in 2024”, the Commission decided to focus the midterm review on taking stock of the implementation of all existing international drug policy commitments and the work to accelerate the implementation of the commitments from 2024 to 2029.

The resolution 66/1 further underscores the important role played by all relevant stakeholders in the implementation of the drug policy commitments.

In this regard, stakeholders, including UN entities, international and regional organizations, as well as NGOs in consultative status with ECOSOC, are invited to submit written contributions on the 11 challenges identified in the 2019 Ministerial Declaration, to inform the preparatory process in the lead-up to 2024. Contributions are posted as received, and the content remains the responsibility of the submitting entities.

United Nations

Office on Drugs and Crime

Stakeholders' Contributions - CND 2024 Midterm Review

Both the range of drugs and drugs markets are expanding and diversifying

Increasing links between drug trafficking, corruption and other forms of organized crime, including trafficking in persons, trafficking in firearms, cybercrime and money-laundering and, in some cases, terrorism, including money-laundering in connection with the financing of terrorism, are observed

The value of confiscated proceeds of crime related to money-laundering arising from drug trafficking at the global level remains low

The criminal misuse of information and communications technologies for illicit drug -related activities is increasing

Responses not in conformity with the three international drug control conventions and not in conformity with applicable international human rights obligations pose a challenge to the implementation of joint commitments based on the principle of common and shared responsibility

Drug treatment and health services continue to fall short of meeting needs and deaths related to drug use have increased

The rate of transmission of HIV, the hepatitis C virus and other blood-borne diseases associated with drug use, including injecting drug use in some countries, remain high

The adverse health consequences of and risks associated with new psychoactive substances have reached alarming levels

Synthetic opioids and the non-medical use of prescription drugs pose increasing risks to public health and safety, as well as scientific, legal and regulatory challenges, including with regard to the scheduling of substances

The availability of internationally controlled substances for medical and scientific purposes, including for the relief of pain and palliative care, remains low to non-existent in many parts of the world

Contributions addressing multiple challenges identified in the 2019 Ministerial Declaration